Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab in anti-MAG neuropathy patients with characteristics of good responders
2021-000009-25Phase 3Active
- Sponsor
- CHU Saint-Etienne
- Start
- Feb 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in anti-myelin-associated glycoprotein neuropathy comparing Rituximab (MabThera) with Placebo (2 arms). Primary endpoint: Change in I-RODS score from baseline to 12 months. Started Feb 2021; status: active.
02
Drugs
rituximab
03
Conditions
anti-myelin-associated glycoprotein neuropathy
Beyond the preview
Go deeper on 2021-000009-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000009-25.